Fig. 3From: Erythropoietin Therapy for Acute Stroke Is Both Safe and BeneficialClinical outcome of patients in the double-blind proof-of-concept trial. (A) Barthel index (rhEPO versus placebo p < 0.05). (B) Modified Rankin scale (rhEPO versus placebo p < 0.07) on day 30. Dead patients received the worst possible score.Back to article page